Publisher Correction: Predicting progression events in multiple myeloma from routine blood work by Maximilian Ferle, Nora Grieb, Markus Kreuz, Jonas Ader, Hartmut Goldschmidt, Elias K. Mai, Uta Bertsch, Uwe Platzbecker, Thomas Neumuth, Kristin Reiche, Alexander Oeser, Maximilian Merz

Get full text

Predicting progression events in multiple myeloma from routine blood work by Maximilian Ferle, Nora Grieb, Markus Kreuz, Jonas Ader, Hartmut Goldschmidt, Elias K. Mai, Uta Bertsch, Uwe Platzbecker, Thomas Neumuth, Kristin Reiche, Alexander Oeser, Maximilian Merz

Get full text

Isatuximab plus bortezomib, lenalidomide, and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma patients: a frailty subgroup analysis of the IMROZ trial by Salomon Manier, Meletios-Athanasios Dimopoulos, Xavier P. Leleu, Philippe Moreau, Michele Cavo, Hartmut Goldschmidt, Robert Z. Orlowski, Muriel Tron, Christina Tekle, Marie-France Brégeault, Andrea T. Shafer, Meral Beksac, Thierry Facon

Get full text

Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial by Hans Salwender, Niels Weinhold, Axel Benner, Kaya Miah, Maximilian Merz, Mathias Haenel, Christian Jehn, Elias Mai, Ekaterina Menis, Igor Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Steffen Luntz, Britta Besemer, Markus Munder, Peter Brossart, Bertram Glass, Hans-Walter Lindemann, Katja Weisel, Christine Hanoun, Paul Schnitzler, Sarah Klemm, Hartmut Goldschmidt, Marc Raab, Ahmet Elmaagacli

Get full text

Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐u... by Elias K. Mai, Axel Nogai, Henk M. Lokhorst, Bronno van derHolt, Sonja Zweegman, Katja C. Weisel, Sandra Croockewit, Anna Jauch, Jens Hillengass, Marian Stevens‐Kroef, Marc S. Raab, Annemiek Broijl, Gerard M. J. Bos, Peter Brossart, Paula Ypma, Christine Hanoun, Uta Bertsch, Thomas Hielscher, Hans J. Salwender, Christoph Scheid, Hartmut Goldschmidt, Pieter Sonneveld

Get full text

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma by Xiang Zhou, Patrick Costello, Anita Schmitt, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Max Topp, Hartmut Goldschmidt, Hermann Einsele, Nikhil C Munshi, Marc S Raab, Joseph Kauer, Thomas Hielscher, Niels Weinhold, Mirco J Friedrich, Sandra Sauer, Leo Rasche, Thomas Luft, Jan H Frenking, Vivien Wagner, Elias K Mai, Christian S Michel, Marina Hajiyianni, Iris Breitkreutz, Omar Nadeem, Adam S Sperling

Get full text

Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial by Lisa B. Leypoldt, Linlin Guo, Britta Besemer, Mathias Hänel, Marc-S. Raab, Christoph Mann, Christian S. Michel, Hans Christian Reinhardt, Igor Wolfgang Blau, Martin Görner, Yon-Dschun Ko, Maike de Wit, Hans Salwender, Christof Scheid, Ullrich Graeven, Rudolf Peceny, Peter Staib, Annette Dieing, Hartmut Goldschmidt, Carsten Bokemeyer, Tanja Zeller, Dirk Westermann, Katja C. Weisel, Raphael Twerenbold, Antonia Beitzen-Heineke

Get full text

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma by Jan H. Frenking, Xiang Zhou, Kai Rejeski, Vivien Wagner, Patrick Costello, Thomas Hielscher, Lilan Gatti, Joseph Kauer, Omar Nadeem, Elias K. Mai, Christian S. Michel, Mirco J. Friedrich, David Sedloev, Niels Weinhold, Hartmut Goldschmidt, Klaus Herfarth, Anita Schmitt, Michael Hundemer, Michael Schmitt, Carsten Müller-Tidow, Max Topp, Hermann Einsele, Peter Dreger, Nikhil C. Munshi, Adam S. Sperling, Leo Rasche, Sandra Sauer, Marc S. Raab

Get full text